Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Therapy Area
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Novel Drug Development Activities and Orphan Drug Designations
4.1.1.2. Rising Demand from Unmet Population with Rare Diseases
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.2.2. XX
4.1.3. Opportunities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Epidemiology
5.4. Pricing Analysis
5.5. Pipeline Analysis
5.6. Patent Analysis
5.7. Regulatory Analysis
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Small Molecules*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Biologic Drugs
6.3.1. Gene Therapies
6.3.2. Monoclonal Antibodies
6.3.3. Others
6.4. Others
7. By Therapy Area
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
7.1.2. Market Attractiveness Index, By Therapy Area
7.2. Oncology*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Hematology Diseases
7.4. Central Nervous System
7.5. Cardiovascular
7.6. Endocrine
7.7. Respiratory
7.8. Immunologic Conditions
7.9. Gastro-Intestinal
7.10. Musculoskeletal
7.11. Dermatology
7.12. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Johnson & Johnson Services, Inc.*
10.1.1. Company Overview
10.1.2. Product Type Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. AbbVie Inc.
10.3. Vertex Pharmaceuticals Incorporated
10.4. AstraZeneca.
10.5. Incyte.
10.6. Biogen.
10.7. Novartis AG
10.8. F. Hoffmann-La Roche Ltd
10.9. Pfizer Inc.
10.10. Bristol-Myers Squibb Company
LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us